EGFR L858R and T790M coexistence before first line therapy in pulmonary adenocarcinoma - case report

被引：0
|
作者：
Sousa, V. [1 ]
Alarcao, A. [1 ]
Ladeirinha, A. F. [1 ]
Reis Silva, M. [1 ]
Balseiro, S. [1 ]
Ferreira, T. [1 ]
d'Aguiar, M. J. [1 ]
Figueiredo, A. [1 ]
Barata, F. [1 ]
Carvalho, L. [1 ]
机构：
[1] UC, IAP, Fac Med, Coimbra, Portugal
来源：
VIRCHOWS ARCHIV | 2018年 / 473卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
E-PS-21-02
引用
收藏
页码：S315 / S315
页数：1
相关论文
共 50 条
  • [41] BIBW 2992, an irreversible dual EGFR/HER2 kinase inhibitor, shows activity on L858R/T790M EGFR mutants.
    Solca, F
    Schweifer, N
    Baum, A
    Rudolph, D
    Amelsberg, A
    Himmelsbach, F
    Beug, H
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9025S - 9025S
  • [42] Structure-based design and synthesis of 2,4-diaminopyrimidines as EGFR L858R/T790M selective inhibitors for NSCLC
    Chen, Lingfeng
    Fu, Weitao
    Feng, Chen
    Qu, Rong
    Tong, Linjiang
    Zheng, Lulu
    Fang, Bo
    Qiu, Yinda
    Hu, Jie
    Cai, Yuepiao
    Feng, Jianpeng
    Xie, Hua
    Ding, Jian
    Liu, Zhiguo
    Liang, Guang
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 140 : 510 - 527
  • [43] Synthesis and evaluation of novel non-covalent binding quinazoline glycoside derivatives targeting the L858R and T790M variants of EGFR
    Zhang, Renshuai
    Chen, Shaopeng
    Zhang, Xiaowei
    Yu, Rilei
    Wan, Shengbiao
    Geng, Meiyu
    Jiang, Tao
    RSC ADVANCES, 2016, 6 (43): : 36857 - 36862
  • [44] Design, synthesis, and evaluation of A-ring-modified lamellarin N analogues as noncovalent inhibitors of the EGFR T790M/L858R mutant
    Fukuda, Tsutomu
    Umeki, Teppei
    Tokushima, Keiji
    Xiang, Gao
    Yoshida, Yuki
    Ishibashi, Fumito
    Oku, Yusuke
    Nishiya, Naoyuki
    Uehara, Yoshimasa
    Iwao, Masatomo
    BIOORGANIC & MEDICINAL CHEMISTRY, 2017, 25 (24) : 6563 - 6580
  • [45] Phase 1 Dose Escalation of PF-06747775 (EGFR-T790M Inhibitor) in Patients with Advanced EGFRm (Del 19 or L858R±T790M) NSCLC
    Husain, Hatim
    Martins, Renato
    Goldberg, Sarah
    Senico, Peggy
    Ma, Wendy
    Masters, Joanna
    Pathan, Nuzhat
    Kim, Dong-Wan
    Socinski, Mark
    Goldberg, Zelanna
    Cho, Byoung Chul
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1185 - S1185
  • [46] EGFR L718V (+)/T790M (-) as a Mechanism of Resistance in Patients with Metastatic Non-small-cell Lung Cancer with EGFR L858R Mutations
    Raez, Luis E.
    Carracedo, Carlos
    Drusbosky, Leylah M.
    Velez, Michel
    Carlisle, Jennifer
    Stinchcombe, Thomas
    CLINICAL LUNG CANCER, 2021, 22 (06) : E817 - E819
  • [47] Lung Cancer: EGFR Inhibitors with Low Nanomolar Activity against a Therapy-Resistant L858R/T790M/C797S Mutant
    Guenther, Marcel
    Juchum, Michael
    Kelter, Gerhard
    Fiebig, Heiner
    Laufer, Stefan
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2016, 55 (36) : 10890 - 10894
  • [48] Synthesis and preclinical evaluation of a molecular probe for imaging lung cancer with L858R/T790M mutation of epidermal growth factor receptor (EGFR)
    Fawwaz, Muammar
    Mishiro, Kenji
    Nishii, Ryuichi
    Shiba, Kazuhiro
    Kinuya, Seigo
    Ogawa, Kazuma
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [49] Psorachromene induces apoptosis and suppresses tumor growth in NSCLC cells harboring EGFR L858R/T790M/C797S
    Wang, Tong-Hong
    Leu, Yann-Lii
    Chen, Chin-Chuan
    Li, Hsin-Jung
    Yang, Shuenn-Chen
    Huang, Kuo-Yen
    Chen, Chi-Yuan
    PHYTOTHERAPY RESEARCH, 2022, 36 (05) : 2116 - 2126
  • [50] Design, Synthesis and Assessment of Novel Molecule against Drug-Resistant Dual Mutant EGFR (T790M/ L858R) to Treat NSCLC
    Kumar, V.
    Gholap, S. L.
    Sehgal, D.
    Inampudi, K. K.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S347 - S347
12345